These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26940556)

  • 1. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
    Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
    Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of serial decline of kidney function to predict mortality and cardiovascular events in patients undergoing coronary angiography.
    Rein P; Saely CH; Vonbank A; Boehnel C; Drexel H
    Am J Cardiol; 2014 Jan; 113(2):215-21. PubMed ID: 24169005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    PLoS One; 2014; 9(12):e114519. PubMed ID: 25531109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF.
    Damman K; Masson S; Lucci D; Gorini M; Urso R; Maggioni AP; Tavazzi L; Tarantini L; Tognoni G; Voors A; Latini R
    J Card Fail; 2017 Jan; 23(1):2-9. PubMed ID: 27638233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
    Byun YS; Lee JH; Arsenault BJ; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2015 Apr; 65(13):1286-1295. PubMed ID: 25835440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ORBIT II sub-analysis: Impact of impaired renal function following treatment of severely calcified coronary lesions with the Orbital Atherectomy System.
    Lee MS; Lee AC; Shlofmitz RA; Martinsen BJ; Hargus NJ; Elder MD; Généreux P; Chambers JW
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):841-848. PubMed ID: 27567020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
    Billings FT; Hendricks PA; Schildcrout JS; Shi Y; Petracek MR; Byrne JG; Brown NJ
    JAMA; 2016 Mar; 315(9):877-88. PubMed ID: 26906014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin.
    Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2).
    Natsuaki M; Furukawa Y; Morimoto T; Sakata R; Kimura T;
    Am J Cardiol; 2012 Dec; 110(11):1568-77. PubMed ID: 22935527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials.
    Vogt L; Bangalore S; Fayyad R; Melamed S; Hovingh GK; DeMicco DA; Waters DD
    J Am Heart Assoc; 2019 May; 8(9):e010827. PubMed ID: 31020900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
    Shepherd J; Kastelein JP; Bittner VA; Carmena R; Deedwania PC; Breazna A; Dobson S; Wilson DJ; Zuckerman AL; Wenger NK;
    Mayo Clin Proc; 2008 Aug; 83(8):870-9. PubMed ID: 18674471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
    Ho JE; Waters DD; Kean A; Wilson DJ; Demicco DA; Breazna A; Wun CC; Deedwania PC; Khush KK;
    Am J Cardiol; 2012 Jun; 109(12):1761-6. PubMed ID: 22459310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.